Skip to main content
logo
Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
15.49
-0.45 (-2.82%)
Sep 9, 2026, 1:15 PM EDT - Market open

Contineum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---50--
Revenue Growth
------
Gross Profit
---50--
Selling, General & Admin
20.7618.7713.667.266.636.29
Research & Development
45.6249.2937.2426.6716.0922.36
Operating Expenses
66.3868.0650.8933.9222.7228.65
Operating Income
-66.38-68.06-50.8916.08-22.72-28.65
Interest Expense
----0.21-0.39-0.33
Interest & Investment Income
8.818.258.914.610.760.08
Other Non Operating Income (Expenses)
0.01-0.17-0.272.7-1.91-0.1
Pretax Income
-57.56-59.98-42.2623.17-24.25-29
Income Tax Expense
---0.45--
Net Income
-57.56-59.98-42.2622.72-24.25-29
Preferred Dividends & Other Adjustments
---19.57--
Net Income to Common
-57.56-59.98-42.263.15-24.25-29
Net Income Growth
------
Shares Outstanding (Basic)
332819222
Shares Outstanding (Diluted)
332819322
Shares Change
29.38%43.14%469.95%51.38%6.35%-
EPS (Basic)
-1.72-2.17-2.181.36-10.81-13.75
EPS (Diluted)
-1.72-2.17-2.180.08-10.81-13.77
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-53.46-55.54-33.3618.94-20.24-26.43
Free Cash Flow Per Share
-1.60-2.00-1.725.58-9.02-12.53
Gross Margin
---100.00%--
Operating Margin
---32.15%--
Profit Margin
---6.29%--
Free Cash Flow Margin
---37.87%--
EBITDA
-66-67.74-50.6416.27-22.39-28.32
EBITDA Margin
---32.54%--
D&A For EBITDA
0.380.320.260.20.330.33
EBIT
-66.38-68.06-50.8916.08-22.72-28.65
EBIT Margin
---32.15%--
Effective Tax Rate
---1.94%--
SEC Filings: 10-K · 10-Q